69 results about "Protein allergy" patented technology

The invention discloses a natural rubber liquid slurry containing chitosan/sericin and a preparation method thereof, and belongs to the field of high polymer chemistry. The invention is characterized in that the preparation method comprises the following steps: respectively preparing a chitosan water solution and a sericin water solution, mixing the two solution, and regulating the pH value of the mixture to 9-11 by using ammonia water and a citric acid solution; and adding the obtained chitosan/sericin mixed solution to a natural latex slurry, adding a laurate surfactant, and mechanically stirring the mixture uniformly to obtain the natural rubber liquid slurry containing chitosan/sericin. The invention has the advantages that the chitosan has the functions of adsorbing water soluble proteins in the latex, inhibiting bacteria and viruses from breeding, and the like; and the sericin has the functions of oxidation resistance, allergy resistance, hydrophilia, oil resistance and the like, thereby enhancing the emulsion phase stability and the preservation effect of the natural latex. In particular, the product obtained by using the method overcomes the defects of short service life, easy aging and sticking, poor oil resistance, initiation of protein allergy and the like in the traditional natural latex product.

The present invention discloses the use of the non-toxic cell-binding B subunit of CT (CTB), and holotoxin CT that is devoid of ADP-ribosylating activity, as adjuvants for enhancing transcutaneous immune response to a co-administered protein allergen. It was found that topical administration of CTB to mice induced serum antibody response against itself comparable to those evoked by CT, but was inefficient at promoting systemic antibody responses against an admixed prototype protein allergen. To the contrary co-administration of either CT or CTB with allergen led to vigorous antigen-specific T cell proliferative responses in lymph nodes draining the cutaneous site of administration and at distant systemic sites. Consistent with these observations, it was found that CTB selectively potentiated Th1-driven responses without affecting Th2-dependent responses. Cutaneously applied CT enhanced serum IgE responses to a co-administered allergen, while CTB partially suppressed epicutaneously induced IgE responses to the same allergen.

A method for preparing powder rich in whey small peptides with molecular weight of 1000 daltons belongs to the technical field of processing dairy products. The main production process thereof is as follows: enzymatic hydrolysis, embedding and homogenization are firstly carried out on concentrated powder (WPC80 powder) containing 80 percent of whey protein, then the powder is prepared by spray drying, and the product can be used as functional ingredients for infant milk powder. The method adopts trypsin for enzymatic hydrolysis, the degree of hydrolysis achieves 20-21 percent, and then hydrophilic-hydrophobic wall materials of 5-10 percent of beta-cyclodextrin and 5-8 percent of lecithin are adopted, so the method can not only bury the bitterness, but also maintain the biological activities of anti-protein allergy and improve the immunity of the whey small peptides with the molecular weight of 1000 daltons to the maximum extent. The method can be applied to the infant formula milk powder and have good effects of improving the ability of anti-protein allergy of the infant milk powder and improving the immunity.

The invention discloses formula milk powder for infants of 0-6 months and capable of preventing lactose intolerance and protein allergy and belongs to the technical field of formula food. Each 100g of the formula milk powder contains 12-18g of concentrated hydrolyzed whey protein powder. The concentrated hydrolyzed whey protein powder contains lactose. Each 100g of the formula milk powder contains 0-0.5g of the lactose. The formula milk powder has the advantages that the formula milk powder is suitable for the infants of 0-6 months and overcomes the symptoms of infant lactose intolerance and milk protein allergy, the concentrated hydrolyzed whey protein is used as the raw material and can well relieve the symptoms of the infant lactose intolerance, docosahexenoic acid, arachidonic acid, 1, 3-dioleoyl 2-palmitoyl triglyceride, prebiotics fructose-oligosaccharide and polydextrose components are added scientifically, lutein and nucleotide components are intensified, and the requirement of various nutritional components needed by the normal growth of the infants can be satisfied.

The invention provides an infant formula milk powder resisting protein allergy and a preparation method thereof. The formula powder contains a whey protein hydrolysate, and the whey protein hydrolysate is prepared by the following method: dissolving per 5.0 g of whey protein powder in 95ml of distilled water, keeping the solution in a water bath at 85 DEG C for 20 min, adjusting the pH value to 7.0, adding trypsin (with activity of 25000U / g), keep the hydrolysis temperature at 40 DEG C, hydrolyzing for 4 h, heating the hydrolysate in a water bath of 85 DEG C for 10 min for enzyme inactivation, centrifuging to remove the precipitate, regulating the pH value to 8.5, adding aminopeptidase (with activity of 10000U / g), and hydrolyzing at 50 DEG C for 6 h. the whey protein hydrolysate used in the formula powder is whey protein depth hydrolysate with hydrolysis degree reaching 48-55%; and the whey protein peptide obtained from hydrolysis is easy for digestion and absorption, and has non allergenic property; and the bitter taste after depth hydrolysis of the whey protein is eliminated, and the taste is easy to accept by infants.

A novel protein allergen Der p VII of Dennatophagoides pteronyssinus is described. A cDNA clone encoding Der p VII was isolated from a lambda gt11 library of D. pteronyssinus cDNA. The nucleic acid sequence of der p VII encodes a 198 residue mature processed protein having a predicted molecular weight of 22,177 daltons. Der p VII protein may be used as the active ingredient in therapeutic composition for the treatment of sensitivity to house dust mites. The protein may also be used in methods of diagnosing such sensitivity.

A medical security level rubber product with sericin modified surface and a preparation method thereof belong to the technical field of the production technology of rubber and latex products. The invention discloses a sericin composite which is used for the rubber product modification so as to increase the medical security. The rubber product is characterized in that sericin, natural polysaccharides, biological protein, bio-enzyme, organic acid and salt coexist according to a certain proportions. The invention also discloses a preparation method of the rubber product. The method is characterized in that sericin composite is coated on the surface of the rubber product; and/or the sericin composite is added in the natural latex to be vulcanized, and the sericin composite migrates to the surface of the rubber product owning to the hydrophilicity during the rubber vulcanization process and forms a hydrophilic protective film so as to prevent the allergenic protein and chemical additives in the rubber product to precipitate. The positive effect of the invention is as follows: the rubber product can be used to modify the latex protein so as to increase the strength of the rubber and reach the aim of not inducing the protein allergic reaction. Therefore, the sericin waste resource is developed for recycling so as to save the resource and protect the environment.

The invention relates to soybean-based infant formula powder and a preparation method thereof. The infant formula powder is mainly refined by using isolated soybean protein, soybean powder, whey powder, whole milk powder, corn starch, white granulated sugar, mineral substance and composite vitamin. In the preparation method, the isolated soybean protein is hydrolyzed by using phytase, so that thehydrolysis rate, the hydrolysis foaming force and the soaking duration of the isolated soybean protein are greatly improved; and after enzymolysis, the nutrition titer of soybean can be remarkably improved. The soybean-based infant formula powder is suitable for infants suffering from milk protein allergy and lactose intolerance, and is also suitable for normal infants.

The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.

Described are compositions and methods for use thereof for prevention or mitigation of allergic reactions in humans and animals. Novel compositions comprised of, e.g., an acidic salt solution of aluminum, calcium or magnesium, are provided for topical or contact application to physically and/or chemically alter an allergenic protein present in the environment and thereby lower the allergenicity of the protein. The compositions of the invention, e.g., comprised of aluminum sulfate, can be used to deactivate many types of proteinaceous allergens such as dust mite and cockroach body dust, animal dander, dried saliva, mold spore antigens, airborne pollen protein and the like. Compositions can be applied on an as needed basis to a wide variety of surfaces, interiors, furniture, pet bedding, plants and the like. The compositions provided may also be utilized to mitigate allergens present on clothing, e.g., for use in commercial dry cleaning or in household laundry applications.

The invention relates to formula milk powder and in particular relates to a cow and goat milk compound infant formula milk powder and a preparation method thereof. The cow and goat milk compound infant formula milk powder comprises the following components in parts by weight: 35-46 parts of milk sugar, 20-43 parts of whole milk goat milk powder or 180-380 parts of fresh goat milk, 8-14 parts of concentrated goat whey protein powder, 8-15 parts of vegetable oil, 0.5-2.5 parts of bovine milk fat, 0.5-1 part of fructo-oligose, 1-1.5 parts of galactooligosaccharide, 0.2-0.6 part of ARA, 0.15-0.5 part of DHA, 0.1-0.2 part of complex vitamins and 0.5-1 part of complex minerals, wherein the fresh goat milk contains 10-13 percent of dry matters. The milk powder disclosed by the invention has the effect of effectively relieving cow milk protein allergy, is fragrant in taste, reasonable in structure, and comprehensive in nutrition, does not have smell of mutton and is close to breast milk.

Described is a process for reducing the antigenicity of sap and products made from the sap of the Hevea brasilisensis plant and other rubber plants. The process involves contacting sap or a latex rubber product with a mono or dialdehyde, a semialdehyde or any chemical containing an aldehyde group, to cross-link antigenic proteins within the sap or the latex product. The cross-linked proteins no longer have the capability to cause an allergic reaction to persons coming into contact with the latex products made by the process of the invention. The cross-linking reaction between the proteins in the latex sap and the aldehyde can take place in the solution used to the final product, or after the final latex product has been formed, or during various intermediate steps of the processes for forming the latex products.

The invention discloses a recombinant human erythropoietin preparation without human albumin. The recombinant human erythropoietin preparation without human albumin is characterized by comprising the following components: dosages of human erythropoietin, 0.1% to 2% (W/V) of amino acid and salt derivatives thereof, 0.001% to 0.01% (V/V) of non-ionic surface active agent, a physiological soluble buffer solution which can control the pH of the preparation to be 5.0 to 8.0, an iso-osmotic agent consisting of 1% to 5% (W/V) of mannitol or 0.1% to 0.9% (W/V) of sodium chloride, and the balance of water. With the adoption of the preparation, the risks of potential virus threats and protein allergy caused by human albumin in use can be avoided, the content accuracy of recombinant human erythropoietin injection can be ensured, and the stability of high-temperature storage is improved.

The cooked shelled egg and Chinese medicinal material are placed in an earthern casserole, water is added, salt is added, sugar is added, then they are boiled for 10min, closed and stored for 48hr, then the egg can be taken out so as to obtain the invented egg product with unique flavour and several health-care functions of nourishing spleen and stomach, warming the middle-jiao to alleviate pain, etc. The above-mentioned Chinese medicinal material includes schisandra fruit, clove, amomum fruit, licorice, star anise and others.

The invention discloses a total-nutrient formula food for preventing protein allergy. The total-nutrient formula food mainly contains carbohydrate, proteins, fat, necessary vitamins and mineral matters and also contains ferment powder, probiotics and prebiotics. According to protein allergy patient nutrition and metabolism characteristics, the total-nutrient formula food is designed. The total-nutrient formula food has a good taste, balanced nutrition and reasonable functions and effectively improves malnutrition.

The invention provides a clinical nutritional formula special for protein allergy. The nutritional formula special for protein allergy is prepared from the following components, by weight, 15-21 partsof protein and amino acids, 11-15 parts of fat, 52-57 parts of carbohydrates, 3.4-4.2 parts of dietary fiber, 1.2-1.8 parts of macroelements, 0.01-0.04 parts of microelements, 0.005-0.02 parts of fat-soluble vitamins, 0.1-0.3 parts of water-soluble vitamin, 0.005-0.11 parts of nucleotides, and 0.02-0.06 parts of natural plant compounds; the invention also provides a method for preparing the aboveclinical nutrition formula. The clinical nutrition formula has the advantage of improving the patient's body mass, enhancing immune function, relieving allergic symptoms and preventing allergic reactions of people with food protein allergies.

The present disclosure relates in part to an emulsion system comprising a waxy starch. The emulsion system is useful, in some embodiments, for incorporation into infant formulas comprising protein equivalent sources, such as formulas designed for individuals with certain protein allergies. Thus, in certain embodiments, the present disclosure relates to a nutritional composition comprising a protein equivalent source comprising a hydrolyzed protein, amino acids, or a mixture thereof, a fat source, a carbohydrate source, and an emulsifier system comprising a waxy starch. The emulsifier system may further include citric acid esters of mono- and di-glycerides or an octenyl succinic acid-modified starch, or both.

Provided is an allergen detecting apparatus that can combine with an allergen microarray chip, and the apparatus comprises a microfluidic chip and a clamping unit. The allergen microarray chip can be any commercial chip and a reaction region of the microfluidic chip is configured to fit tightly with a microarray region of the allergen microarray chip allowing a sample or a reagent to contact with a protein allergen disposed on the microarray region. The present invention also provides a platform comprising a control system configured to automatically perform the mixing/binding reactions of the antibody/antigen in the apparatus of the present invention to achieve a faster, more cost-effective, and accurate detection of allergens.

Isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagolides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, DNA encoding two major D. farinae allergens, Der f I and Der f II and DNA encoding a D. pteronyssinus allergen, Der p I. In addition, the proteins or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.

The invention relates to a powder latex glove and non-powder latex glove dual-purpose production line and a powder latex glove and non-powder latex glove dual-purpose production method. The productionline comprises a rack. A glove die circulation conveying mechanism is arranged on the rack. The glove die circulation conveying mechanism comprises a conveying motor fixed to the rack, a drive chainwheel, a driven chain wheel, a conveying chain, a middle chain wheel, a main guide rail fixed to the rack and an auxiliary guide rail fixed to the rack. The conveying chain is arranged along the mainguide rail. Multiple glove dies matched with the auxiliary guide rail are hinged to the two sides of the conveying chain correspondingly, and a latex glove die cleaning device, a latex glove forming device, a latex glove protein removing and adhesion preventing treatment device, a latex glove hemming device, a latex glove adhesion preventing powder spraying treatment device and a latex glove die releasing device which are located below the glove die circulation conveying mechanism are sequentially arranged on the rack in the glove die circulation conveying direction. By means of the powder latex glove and non-powder latex glove dual-purpose production line and the powder latex glove and non-powder latex glove dual-purpose production method, gloves which are not likely to cause protein allergy and convenient to wear can be produced, and circulated and automatic production is achieved in the whole process.

The present invention provides nucleic acid sequences coding Cyn d I, or at least one fragment thereof or the functional equivalent of such nucleic acid sequences. The present invention also provides expression vectors comprising such nucleic acid sequences and host cells transformed therewith. The present invention further provides isolated Bermuda grass pollen protein allergen Cyn d I or fragments thereof. Isolated Bermuda grass pollen protein allergens or antigenic or allergenic fragments thereof are useful for diagnosing and treating sensitivity in an individual to Bermuda grass pollen allergens.

The invention discloses a method for immobilizing proteins in natural rubber latex by the aid of modified tannin extract. The method is characterized by comprising steps of adding, by weight, more than 0.2 part of solid modified tannin extract into 100 parts of natural rubber latex and carrying out film formation, leaching, drying and vulcanization processing on rubber products according to conventional proportions and processes for the rubber products. The contents of extractable water-soluble proteins in the prepared rubber products are lower than 100 micro-g/dm<2>; the rubber products are natural rubber glove products manufactured by means of impregnation; the natural rubber latex is high-ammonia concentrated latex; the modified tannin extract is a modified product of powdery tannin extract which is a commercially available commodity. The method has the advantages that the modified tannin extract prepared by means of one-step reaction is used as a protein immobilizing agent, accordingly, the problem of protein allergy of existing natural rubber products can be solved, the mechanical properties, the ageing resistance and the hydrophilic performance of the rubber products can be improved, and the application range of tannin extract can be expanded.

The present invention relates to a method for producing derivatives of wild-type protein allergens with reduced allergenic activity, characterized in by the following steps: providing a wild-type protein allergen with an allergenic activity, splicing said wild-type protein allergen into two parts, said two parts having a reduced allergenic activity or lacking allergenic activity and rejoining said two fragments in inverse orientation; as well as allergen derivatives.